New research found that extreme heat is already influencing how people with cancer manage daily life, access care, and make treatment-related decisions. The study highlights the need to integrate environmental risk into cancer care planning, from clinical conversations and appointment planning to caregiver guidance and community support.

Nanjing University researchers report a breakthrough siRNA delivery strategy that transforms the liver into a "biopharmaceutical factory" for targeted cancer therapy. The team developed an In Vivo Self-Assembled (IVSA) system that uses intravenously injected plasmid DNA to program hepatocytes to produce and package EGFR-targeting siRNA into GE11-tagged small extracellular vesicles. These "biomissiles" selectively deliver therapeutic siRNA to EGFR-positive tumors, overcoming the long-standing siRNA delivery challenge without complex in vitro encapsulation. The system demonstrated potent efficacy across EGFR-mutant lung cancer, gastric cancer, and breast cancer models, outperforming traditional targeted drugs while showing minimal off-target toxicity. This plug-and-play platform represents a paradigm shift from conventional drug manufacturing to in vivo biopharmaceutical production, offering a modular, cost-effective approach for personalized cancer gene therapy.